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Update on cancer cachexia (September 2005) . The previous progress reports provided extensive updates. Since then, little additional progress has been made to identify biochemical mechanisms leading to muscle wasting and atrophy. There have been no substantive breakthroughs in development of new animal models of cachexia, identification of additional circulating factors responsible for the syndrome, or the development of novel patient treatments (Tisdale, 2005) . One of the factors identified by Tisdale, a small sulfated polypeptide called proteolysis-inducing factor, PIF (Wyke & Tisdale, 2004) , has been controversial, since another laboratory was unable to reproduce cachexia with the recombinant human factor (Monitto et al 2004) .
Biochemical mechanisms of cachexia: It appears that muscle wasting involves paracrine factors in the microenvironment surrounding muscle, which regulate its overall activity, in particular insulin-like growth factor-I (Glass, 2003) and the TGF-beta superfamily member myostatin, also known as GFD-8, which is a negative regulator of muscle mass. (Roth & Walsh, 2004) . IGF-1 appears to stimulate the P13 kinase/Akt signaling and Foxo transcription factor pathways (Lee et al, 2004; Stitt et al, 2004; Sandri et al, 2004) . The same pathways are activated during muscle wasting in response to multiple causes; so these are likely also to be activated during cancer-induced muscle wasting (Lecker et al, 2004) . Myosin heavy chain is a major substrate for degradation in cachectic skeletal muscle (Acharyya et al, 2004) .
Role of the proteasome. Skeletal muscle proteolysis in cachexia is probably due to increased activity through the proteasomal pathway, rather than via lysosomes or soluble sarcoplasmic proteases. Certain cancer treatments can either enhance or inhibit this muscle degradation pathway. Thus, cancer chemotherapy may alter cachexia in patients. Omega-3 fatty acids and other eicosanoids can regulate the activity of the proteasome, providing a biochemical rationale for the dietary treatment of cancer cachexia. It is not yet clear that activation of proteasomal degradation is the central or the only pathway for muscle wasting in cancer cachexia (Glass, 2003; Lecker, 2003) , but this seems increasingly likely and may involve specific activation in muscle cells of the specific ubiquitin E3 ligases, atrogin and MuRFI (Dehoux et al, 2004; Sachek et al, 2004) . This activation may involve the NFkappaB transcriptional pathway (Wyke & Tisdale, 2005) .
This report summarizes our successful progress to establish that autocrine motility factor/phosphoglucose isomerase is a systemic cachectic factor. It has been known for 50 years to be elevated in patients with advanced, metastatic breast cancer, and we previously observed that it was also elevated in the circulation of nude mice that were cachectic due to advanced breast cancer metastases restricted to bone.
BODY OF FINAL REPORT
Timetable: The award of this grant was made just as the Principal Investigator was moving from the University of Texas to the University of Virginia. Initial work was commenced upon arrival in Charlottesville Virginia in October 2002. A new research associate was recruited to work on this project, Ms. Lisa Wessner, who has learned all of the techniques specific to the project, which has now been active since January 1 of 2003.
Thus, this final report represents work carried out over the two year period from July 2003 through August 2005. The main animal experiments were substantially delayed by an outbreak of the lethal mouse pathogen Burkholderia gladioli (Foley et al, 2004) . Task 9 (Aims 1-3) Analyze data, prepare and submit results for meeting presentations, progress reports, and peer-reviewed publication. Year 0 1-02, throughout.
Total mice requested = 148 [adult female Balb/c & Balb/c nudes, 32 mice were eliminated in deleted Aim 5] . All use of human cell lines and radioisotopes was eliminated with the deletion of Aims 4 & 5. Animal use has been reported separately to the DoD. Since the annual animal usage and progress reports cover different times, the most recent animal usage form did not include the mice that were used in Figures 1 and 2 .
Progress:
Task 1 was completed in the first year.
Task 2 has been completed with a simplified delivery protocol. Animals were given the factor as sterile intraperitoneal (i.p.) injections of protein in PBS at 8 AM, noon, and 4 PM. Blood levels of PGI/AMF were measured at the 4PM time, and the animals were weighed. The injected mouse AMF/PGI was entirely cleared from the blood stream by 24 hours. The previous report includes figures showing a substantial animal experiment in which nude mice were injected 3 time per day for 3 days with 100 [ld of sterile PBS containing purified mouse AMF/PGI or BSA (negative control) at either 150 or 500 ýig of protein per dose. The data demonstrate that 150 [ig doses were ineffective to cause weight loss, while 500 ltg doses caused a statistically highly significant cachexia by 24 hours after the initial injection, which appeared to persist for 24hrs after the cessation of injection following three days of treatment.
Mouse AMF/PGI for these experiments was prepared in E coli and purified by NiNTA chromatography using the 6xHis C-terminal extension. As detailed in the first progress report, these recombinant protein preparations were carefully analyzed for contamination with bacterial endotoxin and determined to be free of this material to well below a level that would cause inflammation in the animals. The laboratory animal personnel report that the AMF/PGI treatments did not cause any apparent pain or discomfort to the mice.
Task 3 was carried out and no changes in the routine histology of the mice was observed. Similarly, for task 4, no changes in plasma concentrations of interleukins 1, 6 or TNFalpha were observed, while changes in a fourth known cachectic mediator, parathryroid hormone-related protein, PTHrP, were not detectable. ft It Tasks 5 and 6 have been completed. The catalytically inactive mutant E357A was been constructed, expressed and purified. In collaboration with Dr Christopher Davis at the University of South Carolina, the x-ray crystal structure of this mutant was been determined. The data were originally included in the manuscript published in J Mol Biol, as Solomons et al (below under Research Accomplishments), but the data on the mutant were removed to keep the paper within acceptable page limits and will be submitted later. The role of isomerase (PGI) activity in relation to autocrine motility factor (AMF) activity appears no longer to be controversial in the field. We (Davies et al, 2003) and others (Arsenieva & Jefferey, 2002) , have shown that ligand binding to mammalian PGIs results in only very small conformational changes in the surface of the protein away from the active site (where binding to the AMF receptor almost certainly takes place). These conformational changes are almost certainly insufficient to have any effect on a receptor-mediated cytokine-like action of the protein. We believed that mouse E357A AMF/PGI would be active in the cachexia assay. This was proposed in Task 7, which was carried out during 2005. This experiment was entirely unsuccessful. During the course of our work with the model, we made successive improvements in the animal husbandry; such that repetitive anesthesias and retro-orbital blooding drawing were eliminated. These changes resulted in a substantial reduction in physiological stresses on the mice to the point that they no longer lost body mass in response to repeated injections of the AMF/PGI protein at does that were previously cachectic. Since these does were already high, we concluded that Task 7, although completed, was an experimental failure that was impractical to pursue further. Since Task 7 failed to produce cachectic mice, we had no specimens on which to complete Task 8.
We are now carrying out Task 8, the cachexia model, with mice carrying the CHO-1C6 tumor cell line or its control CHO-KI. The 1C6 cells secrete mouse AMF/PGI. Use of this line makes it impossible for us to compare in vivo the species-specific actions of mouse versus human AMF/PGI proteins, since a human PGI-secreting cell line is not available. Details of this model are provided in the appended pdf documents from the P.I.'s presentations at the 2005 DoD-sponsored Era of Hope meeting. Mice with tumors and cachexia will be sacrificed and tumor, adjacent muscle, and matched contralateral muscles harvested. Muscle RNAs will be assayed by real-time PCR with mouse-specific primer pairs for a series of markers: IGF-1, myostatin, atrogin, MuRF-1, myosin heavy chain, and Foxo 3. We will also prepare muscle homogenates from treated and control mice and assay them for proteasomal activity (Reinheckel et al, 2000) as was shown in figure 3 of the previous report. Task 9. We have published several papers on the AMF/PGI and several reviews on bone metastases including discussions of metastasis-associated cachexia. Most recently we have published an animal model of metastasis (albeit of bladder cancer) to the lung, in which metastasis is suppressed by the signaling regulator Rho GDI2 (Titus et al, 2005) . We found that the two major targets of metastasis suppression by Rho GDI2 were endothelin-1 and neuromedin U. The focus of the Titus et al paper was the role of endothelin in metastases, which were effectively decreased by an orally active endothelin antagonist already in clinical trials. We are currently pursuing the role of neuromedin U, particularly since this molecule can cause weight loss in overexpressing animals (Kowalski et al, 2005) and is likely to be an important mediator of cancer anorexia and perhaps cachexia. We have preliminary data that these same gene regulatory pathways and responses also occur in breast cancer cell lines. We have not yet published the details of our two animal models in which AMF/PGI causes cachexia. These two papers would be greatly strengthened by a demonstration of molecular effects on muscle protein degradation in vivo. The final animal experiment should provide these missing data and will permit us to submit these final publications in 2006.
SUPPORTING DATA
This document is accompanied by three appendices, two of which are pdfs of the presentations (PowerePoint and Poster) made by the P.I. These two presentation pdfs provide extensive illustrations of the points described above.
KEY RESEARCH ACCOMPLISHMENTS:
1) Purification of recombinant AMF/PGI with low endotoxin content finalized.
2) Animal model of direct i.p. injection of mouse AMF/PGI used to cause statistically significant (4%) weight loss in 24hrs compared to equivalent control protein treatment. Partial doseresponse established between 450 (ineffective) and 1500 (effective) rtg/mouse/day. Data are shown in Figures 1 and 2 , below. (Titus et al, 2005) . Neuromedin U causes weight loss in mice (Kowalski et al, 2005) and we are pursuing studies with this new animal model.
REPORTABLE OUTCOMES (previous two years):
Twelve manuscripts published, which include reviews of the contributions of bone metastases to cancer cachexia, while two papers (*'ed) derive directly form the work carried out for this proposal:
CONCLUSIONS
Purified mouse autocrine motility factor/phosphoglucose isomerase causes statistically weight loss (cachexia) after 3 days of 3X daily intraperitoneal injection at a dose of 0.5 mg/injection, which was accompanied by significant increases in serum concentrations of the factor. This is a simpler animal model than originally proposed. Thus, the main hypothesis of the original proposal has been validated. The injection model, while establishing that AMF/PGI protein is a causal agent for cachexia, has not been practical as animal model for the detailed structure/function analysis of the factor. It has also not been practical as a model for the elucidation of the molecular mechanisms by which the factor is presumed to activating skeletal muscle proteolysis. We are completing the project with an additional experiment using a tumor bearing animal model that in our hands reliably causes cachexia. We will use this to identify genes activated in skeletal muscle in response to secreted AMF/PGI protein and to test whether such gene activation occurs locally adjacent to tumors or is systemic.
Structures of the AMF/PGI proteins, including mouse and human proteins and the enzyme complexed with inhibitor have been solved by x-ray crystallography and published or accepted for publication. Mutant forms of the protein have been prepared. Experiments have been successfully completed to improve the purity of the recombinant protein and to characterize the effects of the factor on both intact animals and on a mouse muscle cell line in vitro. The structural data are now complete for understanding the species-specific effects and their structural bases. Protocol was similar to that described under Figure 1 , except that the injections were of 500 ug aliquots of the proteins, in the same volume of PBS as before. There were n = 5 mice per group. The curves were analyzed for statistical significance by 2-way ANOVA, and p < 0.0001. Significance of differences between the two curves at each time point were calculated by comparing replicates of the means by row with Bonferroni's post-test using the statistics programs in GraphPad Prizm. ** p < 0.01; *** p < 0.001. Other points n.s. (p > 0.05). 
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-~r . This finding was confirmed by examining the relationship 65 (16): 7320-7) between RhoGDI2 expression levels and those of ET-1 in human tumor samples and cell lines. Collectively, our findings indicate that Introduction adjuvant trials with endothelin antagonists may be considered for patients with advanced bladder cancer following therapy of the An estimated 53,000 new cases of bladder cancer are diagnosed primary lesion. In addition, application of this approach to other in the United States each year. Approximately 5% of these patients metastasis suppressor genes could identify potential novel targets present with metastatic disease at diagnosis. However, an for therapy in other common malignancies (6, 7) . additional 50% of patients who are originally diagnosed with locally advanced disease later develop metastases, commonly to Materials and Methods the lung, resulting in significant mortality among patients with Gene expression profiling of bladder tumor cell lines and human bladder cancer (1, 2) . The molecular basis of pulmonary metastases bladder cancers. Isogenic T24T cells, bladder carcinoma-derived cell is not well understood but is likely to involve the progressive loss of lines, primary human bladder carcinomas, and normal bladder tissues suppressor genes and dominant gain of function mutations in were profiled on HG-U133A GeneChip arrays (Affymetrix, Santa Clara, critical pathways along steps of the metastatic cascade (3).
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CA). For the previously described isogenic T24T cell pair containing vector Whereas in theory, the metastatic cascade could be interrupted or RhoGDI2 constructs (4), duplicate RNA samples were generated from at various points with equal potential for therapeutic benefit, only independent cell cultures; >80% cancer cells were processed for RNA isolation. RNA was processed as experiments were carried out twice or more and results pooled for the previously described and hybridized to HG-U133A GeneChip arrays statistical analysis. (Affymetrix). Image files were assessed for quality and artifacts and Statistical methods. Expression levels were transformed to the natural processed using Microarray Analysis Suite 5.0 (MAS 5.0, Affymetrix) using log scale to stabilize the variance. The Pearson correlation coefficient was a scaling factor of 200.
used to assess the relationship between the log ratios of ET-I to RhoGDI2 Genes associated with RhoGDI2 expression in T24T cells were identified and NmU to RhoGDI2. F tests were used to assess trends in the fold changes using the local-pooled error (LPE) test (8) with a false discovery rate (FDR) in HOst, pcDNA3, and RhoGDI2 with the addition of varying levels of ET-1. P < 0.05. Functional relationships among genes correlated with RhoGDI2 X 2 tests were used to compare the proportion of mice developing expression were analyzed using the ontology use in dCHIPl.3/ChipInfo metastases in the pcDNA3, RhoGDI2 and the pcDNA3 + atrasentan groups. (9, 10) . The P value generated by this method indicates the strength of the For each group, exact 95% confidence intervals based on the binomial association of gene clusters to the gene ontology terms or pathways, with distribution were used for the proportion of mice with metastases. P < 0.05 considered significant. We sought to identify genes encoding secreted proteins using two parallel approaches as previously described Results (11). To identify which of the 20 RhoGDI2-suppressed genes exhibited Previous microarray analysis of a nonmetastatic human bladder expression correlated with tumor stage, tumors with stage Ta were cancer cell line, T24 and a lineage-related lung metastatic variant, compared with tumors of stage TI and above; these were then ranked T24T, revealed the loss of expression of several genes, including the according to fold change.
GDP dissociation inhibitor, RhoGDI2. Following reexpression in Neuromedin-U and endothelin axis evaluation in bladder cancer cells. T24T cells stably transfected and expressing RhoGDI2 transgene T24T cells, RhoGD12 functions as a potent suppressor of lung (T24T-RhoGDI2) or vector control (T24T-pcDNA3) were washed with PBS metastasis (4) . We have also shown that RhoGDI2 gene expression and total genomic RNA isolated and used as template for reverse correlates with metastatic competence in bladder carcinomatranscription-PCR (RT-PCR) using primers for Neuromedin-U (NmU), derived cell xenografts and have shown here that RhoGDI2 protein ET-1, ET-I-converting enzyme, endothelin A receptor, and endothelin B expression is also decreased as a function of increased metastatic receptor selected using OligoLite primer analysis software. Amplification capability in a series of human bladder cell lines (Fig. 1A) . To begin was normalized to glyceraldehyde-3-phosphate dehydrogenase. A Qiagen to understand the mechanism by which RhoGDI2 suppresses One-step RT-PCR kit was used following the manufacturer's instructions, metastasis, we reasoned that genes downstream of RhoGDI2 T24T, T24T-RhoGDI2, or T24T-pcDNA3 were plated and grown to 80% activity in bladder cancer patients may be down-regulated by confluence in DMEM/F-12 + 5% fetal bovine serum. Then, the plates were activity in r patiensmye d egulated by washed with PBS and 14 mL DMEM/F-12 without serum was added. Cells reexpression of RhoGDI2 in RhoGDI2-deficient, metastatic cells. To were incubated in the above conditions for 36 hours. Medium was removed determine the identity of these genes, stable T24T derivative from the cells and analyzed by commercial ELISA assay (R&D Systems, Inc., bladder cancer cells were selected with empty vector or a construct Minneapolis, MN) according to the supplier's instructions, expressing RhoGDI2 (Fig. 1A) . RNA from these cells was hybridized Phospho-Erkl/2 evaluation in RhoGDI2-transfected cells stimulated to a microarray (11) containing -21,500 human genes. Sixty-three with Endothelin-1. HOst, T24T-RhoGDI2, or T24T-pcDNA3 were serum and 40 genes were up-regulated and down-regulated by >2-fold, starved overnight. Before lysis, cells were subjected to a 20-minute exposure respectively, in RhoGDI2-expressing cells. Analysis of the data with of vehicle or varying concentrations of ET-1 (Sigma, St. Louis, MO). HOst respect to gene sequence and GO annotations indicated that cells were obtained from Cambrex (Walkersville, MD) and are Normal several of these encode putatively secreted proteins that may be Human Osteoblasts (http://www.cambrex.com). Cells were then washed on involved in autocrine or paracrine signaling ( Table 1 ). An ice in BioPlex Cell Wash Buffer followed by addition of 300 gL of BioPlex Lysis Buffer (containing phenylmethylsulfonyl fluoride and BioPlex ontological view of these genes (Table 2) revealed that many are phosphatase inhibitors), scraped and agitated on a microplate shaker.
involved in cytoskeletal organization providing potential insight Protein concentration was determined by bicinchoninic acid assay buffer into the mechanism of action of RhoGD12. (Pierce, Rockford, IL) and allowed to incubate with phospho-Erkl/2-To determine which of the 40 down-regulated genes in stable coupled beads (Bio-Rad, Richmond, CA) overnight. The lysate/bead mixture RhoGDI2 T24T transfectants may be clinically relevant targets, we was then washed and exposed to phospho-Erkl/2 detection antibody and searched for genes whose expression was increased as a function of then allowed to incubate with Streptavidin-PE for 10 minutes, in the dark.
tumor stage in a series of 20 human bladder cancers using Captured lysates were washed again and resuspended in BioPlex microarray analysis. Tumor tissue from lung metastases is not Resuspension Buffer before analysis. All assay samples were run in multiple available from bladder cancer patients. This is primarily because biological replicates and tested in duplicate, removal of metastases in patients with bladder cancer is not In vitro and in vivo growth and metastasis assays. Growth and colony formation in soft agar of T24T-RhoGDI2 or T24T-pcDNA3cells was analyzed required for routine medical care. Therefore, we evaluated gene + atrasentan using techniques previously described (4, 12) . S.c. tumorigeexpression from primary human bladder carcinomas according to nicity in 6-week-old nude mice was evaluated as described (13) with 5 × I06 pathologic stage, as the frequency of metastasis robustly increases cells in 0.1 mL of SFM. For experimental metastasis, mice were given an i.v. with higher tumor stage (15) (16) (17) . Whereas 28 genes were uplateral tail vein injection with 106 tumor cells suspended in 0.1 mL of SFM as regulated in association with increasing stage, only two of these described (13) . At the time of euthanasia, the lungs were removed by were also down-regulated by stable RhoGDI2 expression in the cell dissection away from adjacent organs and examined grossly and microscopline model (Table 1) . The relationship between expression of these ically as described (4) . RhoGDI2 immunohistochemistry on lung samples was two genes and tumor stage is shown in Fig. lB . In the T24T cell line carried out and scored as described (5) without knowledge of the system, the most strongly down-regulated mRNA in response to experimental groups (atrasentan or vehicle/pcDNA3 or RhoGDI2) by the RhoGDi2 was ET-1, which was decreased 9.5-fold (Table 1) , whereas pathologist (H.F.F). The presence, number, and size of metastatic deposits NmU was decreased 3-fold. These microarray expression levels were evaluated. For both s.c. tumorigenicity and experimental metastasis NmUewasdeeased 3-fold. These aray e si on levels experiments, animals were separated into two groups: group 1, pcDNA3 were independently verified by RT-PCR analysis (Fig. 1C) . As ET-1 is transfected cells and group 2, pcDNA3 + atrasentan. Mice were treated with a secreted factor that requires enzymatic processing to generate either atrasentan (5 mg/kg/d) in their drinking water or not (control water) the mature active form by endothelin-converting enzyme (ECE), we for 12 weeks. This dose of atrasentan has previously been shown to give tested conditioned media from both RhoGDI2 stably transfected effective serum concentrations of the drug in nude mice (14) . In vivo and vector control cell lines for the presence of active ET-1 protein. Ta, five T1 , six T2, three T3, and four T4) was macrodissected and areas comprised of >80% viable carcinoma was used for expression profiling using the Affymetrix HG-U133A array as described. Columns, mean Affymetrix expression levels as a function of stage; bars, SD. Both Et-1 (P = 0.004) and NmU (P = 0.001), which show significant increases in expression levels across stage, assuming a linear trend in the In(expression level). C, expression of ET-1, NmU, and endothelin receptor A (ETa) in RhoGDI2-and vector-transfected cells. RT-PCR was done with primers specific for NmU and ET-1 as described in Materials and Methods. The template used was RNA isolated from T24T-RhoGDI2 and T24T-pcDNA3 cells. D, expression ET-1 and NmU as a function of RhoGDI2 in bladder cancer cell lines. Forty-one human bladder cell lines were analyzed on oligonucleotide arrays for the expression levels of RhoGDI2, NmU, and ET-1. Ratio of NmU to RhoGDI2 expression (X-axis); ratio of endothelin to RhoGDI2 expression (Y-axis). Regression line is shown. Correlation = 0.85; 95% confidence interval, 0.78-0.90; P < 0.001.
In RhoGDI2-expressing cells, ET-1 was present at a concentration genesis (18) . Hence, we sought to evaluate this axis by examining of 7 pg/mL, whereas in vector control cells, ET-1 was present at the microarray data and confirming these findings by RT-PCR 69 pg/mL, showing that RhoGDI2 affects the active levels of this analysis. These data showed that vector-transfected T24T cells secreted pepiide.
express mRNAs for the two endothelin receptors, endothelin A To further explore the relationship between RhoGDI2 expression receptor (ETaR) and endothelin B receptor (ETbR), as well as the with that of ET-1 and NmU in bladder cancer, microarray data from ECE. Although mRNA expression of these three genes was 41 human bladder cancer cell lines were viewed as a logarithmic uniformly lower in RhoGDI2-transfected cells, this did not reach plot of the ratio of ET-1 to RhoGDI2 versus ratio of NmU to statistical significance (data not shown). Because we had previously RhoGDI2. The log-linear relationship suggests a codependent established that ET-1 is produced in the medium conditioned by relationship between RhoGDI2 and both ET-1 and NmU expression the vector-transfected cells, we sought to determine whether this ( Fig. ID; correlation between log ratios, 0.85; 95% confidence ET-1 plays a role in cell growth in vitro and in vivo, using the interval, 0.78-0.90; P < 0.001). Taken together with data from the selective ETaR antagonist, atrasentan. ETaR blockade was shown to RhoGDI2 transfection studies in T24T cells and the human bladder have no effect on growth in monolayer culture ( Fig. 2A) or to affect carcinoma data, this finding independently supports and generalthe anchorage-independent colony forming ability of RhoGDI2-izes the importance of RhoGDI2 regulation of ET-1 and NmU in stable or empty vector transfected cells (Fig. 2B ). In addition, no human bladder cancer. difference in local tumor growth was observed following s.c. The endothelin axis is composed of several members that can be injection of immunocompromised mice with vector and RhoGDI2-expressed by both cancer cells and host cells resulting in both transfected T24T cells and treated with atrasentan or vehicle for autocrine and paracrine interactions favoring growth and angio-8 weeks.
RhoGDI2 Suppresses Metastasis by Down-Regulating ET-1
ET-I is known to induce cell proliferation and differentiation cancer cells, suggesting the possibility that these cells are through multiple G-protein-linked signaling systems (14). Studies insensitive to ET-1 by virtue of receptor loss or defects in have also shown that ET-1 induces a biphasic activation of signaling. However, as shown above (Fig. IC) , these cells do p2lras, which subsequently activates the extracellular signalexpress the ET-1 receptor, ETaR. Evaluation of the effect of ET-1 regulated kinase (Erk) cascade (19). Our cumulative data above on Erk phosphorylation revealed sensitivity of these cells to ET-1. shows that blockade of the autocrine endothelin axis does not
In contrast, reexpression of RhoGDI2 resulted in a marked have an effect on in vitro growth or colony formation in bladder blockade of this effect, suggesting that this protein blocks the The endothelin axis, specifically ET-1, is known to be important 6 20000 for the regulation of multiple biological processes including • 50 angiogenesis in the normal lung (14, 20) . Furthermore, ET-1 is a known angiogenic factor responsible for the tumor vasculature of r 12000 cancers that metastasize to the lung (14, 21) . Taken together with the results presented above, we reasoned that the paracrine effects E 00 Z. of pulmonary ET-1-coupled with the autocrine effects of tumor ET- To test this hypothesis, we injected stably transfected T24T Cell Line vector or RhoGDI2 overexpressing cells into the tail veins of ten 8-
Parent pcDNA3
RhaGDI2 week-old nude mice, which were subsequently exposed to drinking Atrasentan + + + -water containing atrasentan or vehicle. After 8 weeks, the lungs h were inspected grossly and microscopically (Fig. 3A) . Fifty-three *Number of genes found to be significantly changed (increased or decreased) as a function of RhoGDI2 in the corresponding ontology percent of the mice receiving the stable T24T-empty vector cells class, developed lung metastases. This was reduced to 5% by treatment tCalculated with dCHIP v1.3. Values < 0.05 considered significant for with atrasentan. Mice exposed to RhoGDI2-overexpressing cells association of genes to the gene ontology terms or pathways had a 20% incidence of lung metastases. In control mice, the discovered.
tumor size of metastases ranged from 0.8 to 6 mm compared with tNumber of genes with specific annotated ontology on entire chip. Figure 3 . A, in vivo lung metastasis in mice injected with bladder cancer cells., i, Mice in each of two groups were injected s.c. with T24T-RhoGDI2 and T24T-pcDNA3 cells. After randomization, one group of mice received atrasentan in their drinking water, the other group received vehicle. Animals were euthanized at 12 weeks and lungs examined grossly and then processed for microscopy and immunohistochemistry as described in Materials and Methods. ii, a plot of incidence of lung metastasis from four independent experiments. Columns, means; bars, SD. The groups are significantly different with respect to the proportion of mice with lung metastases (P < 0.0001, X 2 test). B, histologic appearance of lung metastases: H&E-stained sections [H&E, x40 (i) and x200 (i')] and immunohistochemical (iii) staining for RhoGDl2 in pulmonary metastases obtained from RhoGDl2-transfected T24T bladder cancer cells injected iv. via tail vein. Avidin-biotin immunoperoxidase technique described in Materials and Methods is shown at x400 magnification. C, diagrammatic representation of the autocrine and paracrine effects of RhoGDI2 on the endothelin axis in bladder cancer lung metastasis. Abbreviation: preproendothelin-1, pET-I.
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Cancer Research of metastases per mouse was 25.3 (range, 20-80) in the control proliferation of endothelial and vascular smooth muscle cells thus group, 3.4 (range, 0-6) for those with RhoGDI2-overexpressing promoting tumor growth. Previous work also shows a role for cells, and 1.0 (range, 0-2) in the group treated with atrasentan.
tumor-secreted ET-1 in skeletal metastases from breast and Overall, this indicates that the effect of atrasentan in suppressing prostate cancers (14) and supports a cyclical model in which metastasis mediated by the loss of RhoDGI2 is similar to tumor-secreted ET-1 stimulates bone cells, in turn providing a reexpression of the gene itself. Careful microscopic examination fertile microenvironment for metastases (27) . A similar cycle could of cancer cell morphology, percent tumor necrosis and location of occur in other in endothelin-responsive tissues, such as the lung metastatic foci relative to the vasculature did not differ between and kidney (24, 28) and may be the primary driving force for lung groups (Fig. 3B, i and ii; data not shown) . Immunohistochemical metastasis. Further evidence for this model comes from the analyses of lung metastases in mice with RhoGDI2-transfected observation that neither RhoGDI2 reconstitution nor atrasentan T24T cells using an anti-lhoGDI2 antibody (Fig. 3B, iii) showed treatment altered primary tumor growth, suggesting that both that -70% to 90% of the tumor cells expressed the protein. This act at the metastatic site, likely in breaking paracrine signaling observation suggests that the cells may have developed compen- (Fig. 3C) (23) of P-catenin and therefore P-catenin/TCF-4-mediated tranIn conclusion, we have applied a novel approach to identify scription are also important examples of up-regulated genes and druggable targets which become activated following the loss of pathways that become activated following the loss of tumor RhoGDI2 expression. We provide strong support for this concept suppressor genes. Here, we show that the inhibition of the in vivo by showing that an ETA antagonist effectively decreased endothelin axis, mediated by the blockade of up-regulated lung metastases in a bladder cancer animal model thus validating functional ET-1 ligand, leads to metastatic suppression in cells FT-i as a novel therapeutic target in lung metastasis. These deficient for RhoGDI2. Indeed, inhibition of the endothelin axis is findings suggest that clinical inhibition of ET-1 activity might be particularly attractive, because we find no evidence for loss of considered in clinical trials of patients with bladder cancer organismal or tissue viability, seeking to reduce the frequency of relapse with pulmonary
The endothelin ligand has been shown to regulate vascular tone, metastasis.
tissue differentiation, cell proliferation, hormone production, cell invasion, angiogenesis, and bone remodeling (18) . ET-1 also has potent effects on cells in the skeleton (18) and lung (24), two
